期刊
EXPERT REVIEW OF HEMATOLOGY
卷 3, 期 2, 页码 175-186出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.10.14
关键词
acute lymphoblastic leukemia; acute megakaryocytic leukemia; acute myeloid leukemia; Down syndrome; GATA1 transcription factor; JAK2
类别
资金
- NCI [RO1 CA120772]
- Leukemia Research Life
- Elana Fund
- Justin's Gift Charity
- Children's Research Center of Michigan
- St. Baldrick's Foundation
- Ring Screw Textron Chair in Pediatric Cancer Research
- NATIONAL CANCER INSTITUTE [R01CA120772] Funding Source: NIH RePORTER
Acute leukemias in children with Down syndrome (DS) are characterized by unique clinical and biological features. Notable among DS children with acute myeloid leukemia (AML), is the high frequency of the acute megakaryocytic leukemia (AMkL) subtype, which uniformly harbor somatic mutations in the transcription factor GATA1 gene. DS patients with AML, and in particular AMkL, have event-free survival rates of 80-100% in contrast to event-free survival rates of less than 35% for non-DS children with AMkL. DS children with acute lymphoblastic leukemia have a more heterogeneous disease, with approximately 30% of the patients having somatic JAK2 mutations, heightened methotrexate sensitivity and higher rates of treatment-related toxicities. These features highlight a striking relationship between genes localized to chromosome 21, leukemogenesis and sensitivity to leukemia chemotherapy agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据